Powl Brian T.'s Form 4 filing
Kura Oncology, Inc. (KURA) · filed Sep 29, 2026
- Accession no.
- 0001193125-26-407935
- Filed
- Sep 29, 2026, 6:30 PM ET
- Trade date
- Sep 28-29, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $345.0K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Powl Brian T.CIK 0001934232 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | Common Stock | SSaleDisposed | −9,020 | $10.50 | −$94,685.65 | 160,249 | Direct | |
| Sep 28, 2026 | Common Stock | SSaleDisposed | −8,000 | $10.56F3 | −$84,497.6 | 152,249 | Direct | |
| Sep 29, 2026 | Common Stock | SSaleDisposed | −15,430 | $10.75F5 | −$165,852.44 | 136,819 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $10.40 to $10.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $10.55 to $10.90. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.